Role of MEN2A-derived RET in maintenace and proliferation of medullary thyroid carcinoma

Journal of the National Cancer Institute

Volumn 96, Issue 16, 2004, Pages 1231-1239

  Drosten, Matthias ^a   Hilken, Gero ^b   Böckmann, Miriam ^a   Rödicker, Florian ^a   Mise, Nikica ^a   Cranston, Aaron N ^c   Dahmen, Uta ^b   Ponder, Bruce A J ^c   Pützer, Brigitte M ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CELL CYCLE PROTEIN; CYCLIN D1; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; PROTEIN RET; AKT1 PROTEIN, HUMAN; BROXURIDINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; RET PROTEIN, HUMAN; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER GROWTH; CARCINOMA CELL; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MEDULLARY CARCINOMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SIPPLE SYNDROME; THYROID CARCINOMA; TRANSGENIC MOUSE; TUMOR VOLUME; ADENOVIRUS; ANIMAL; CELL DIVISION; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; METABOLISM; PHOSPHORYLATION; THYROID TUMOR; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; BROMODEOXYURIDINE; CARCINOMA, MEDULLARY; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; ONCOGENE PROTEINS; ONCOGENE PROTEINS, FUSION; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TETRAZOLIUM SALTS; THIAZOLES; THYROID NEOPLASMS;

EID: 4344566311     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh226     Document Type: Article

References (45)

1. Gimm O. Thyroid cancer. Cancer Lett 2001;163:143-56.
2. Hundahl SA, Fleming ID, Fremgen AN, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998;83:2638-48.
3. Vitale G, Caraglia M, Ciccarelli A, Lupoli G, Abbruzzese A, Tagliaferri P, et al. Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 2001;91:1797-808.
4. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-60.
5. Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 1995;15:1613-9.
6. Manie S, Santoro M, Fusco A, Billaud M. The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet 2001;17:580-9.
7. Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, Pachnis V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 1994;367:380-3.
8. Ponder BA, Smith D. The MEN II syndromes and the role of the ret proto-oncogene. Adv Cancer Res 1996;70:179-222.
9. Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol 1999;17:380-93.
10. Hansford D, Mulligan LM. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet 2000;37:817-27.
11. Takahashi M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 2001;12:361-73.
12. van Weering DH, Bos JL. Signal transduction by the receptor tyrosine kinase Ret. Recent Results Cancer Res 1998;154:271-81.
13. Melillo RM, Santoro M, Ong SH, Billaud M, Fusco A, Hadari YR, et al. Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade. Mol Cell Biol 2001;21:4177-87.
14. Besset V, Scott RP, Ibanez CF. Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-RET receptor tyrosine kinase. J Biol Chem 2000;275:39159-66.
15. Segouffin-Cariou C, Billaud M. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem 2000;275:3568-76.
16. Baldassarre G, Bruni P, Boccia A, Salvatore G, Melillo RM, Motti ML, et al. Glial cell line-derived neurotrophic factor induces proliferative inhibition of NT2/D1 cells through RET-mediated up-regulation of the cyclin-dependent kinase inhibitor p27(kip1). Oncogene 2002;21:1739-49.
17. Carlomagno F, Salvatore D, Santoro M, de Franciscis V, Quadro L, Panariello A, et al. Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 1995;207:1022-8.
18. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998;95:2509-14.
19. Drosten M, Stiewe T, Putzer BM. Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model. Hum Gene Ther 2003;14:971-82.
20. Rodicker F, Putzer BM. p73 is effective in p53-null pancreatic cancer cells resistant to wildtype TP53 gene replacement. Cancer Res 2003;63:2737-41.
21. Putzer BM, Stiewe T, Crespo F, Esche H. Improved safety through tamoxifen-regulated induction of cytotoxic genes delivered by Ad vectors for cancer gene therapy. Gene Ther 2000;7:1317-25.
22. Reynolds L, Jones K, Winton DJ, Cranston A, Houghton C, Howard L, et al. C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RET. Oncogene 2001;20:3986-94.
23. Addison CL, Braciak T, Ralston R, Muller WJ, Gauldie J, Graham FL. Intratumoral injection of an adenovirus expressing interkeukin 2 induced regression and immunity in murine breast cancer model. Proc Natl Acad Sci U S A 1995;92:8522-6.
24. Cranston AN, Ponder BA. Modulation of medullary thyroid carcinoma penetrance suggests the presence of modifier genes in a RET transgenic mouse model. Cancer Res 2003;63:4777-80.
25. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
26. Chang F, Lee JT, Navolanic PM, Steelman RS, Shelton JG, Blalock WL, et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003;17:590-603.
27. Roovers K, Assoian RK. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays 2000;22:818-26.
28. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999;401:86-90.
29. Grossmann M, O'Reilly LA, Gugasyan R, Strasser A, Adams JM, Gerondakis S. The anti-apoptotic activities of Rel and RelA required during B-cell maturation involve the regulation of Bcl-2 expression. EMBO J 2000;19:6351-60.
30. Reed JC. Mechanisms of apoptosis. Am J Pathol 2000;157:1415-30.
31. Watanabe T, Ichihara M, Hashimoto M, Shimono K, Shimoyama Y, Nagasaka T, et al. Characterization of gene expression induced by RET with MEN2A or MEN2B mutation. Am J Pathol 2002;161:249-56.
32. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002;4:E131-6.
33. Medema RH, Kops GJ, Bos JL, Burgering BM. AFX-like Forkhead transcription factors mediate cell cycle regulation by Ras and PKB through p27kip1. Nature 2000;404:782-7.
34. Schuringa JJ, Wojtachnio K, Hagens W, Vellenga E, Buys CH, Hofstra R, et al. MEN2A-RET-induced cellular transformation by activation of STAT3. Oncogene 2001;20:5350-8.
35. Rossig L, Jadidi AS, Urbich C, Badorff C, Zeiher AM, Dimmeler S. Akt-dependent phophorylation of p21 (Cip1) regulates PCNA binding and proliferation of endothelial cells. Mol Cell Biol 2001;21:5644-57.
36. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12:3499-511.
37. Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF, Testa JR. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci U S A 2001;98:247-52.
38. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164-72.
39. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol 3-kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002;62:4132-41.
40. Danilkovitch-Miagkova A. Oncogenic signaling pathways activated by RON receptor tyrosine kinase. Curr Cancer Drug Targets 2003;3:31-40.
41. Wang DG, Liu WH, Johnston CF, Sloan JM, Buchanan KD. Bcl-2 and c-Myc, but not bax and p53, are expressed during human medullary thyroid carcinoma tumorigenesis. Am J Pathol 1998;152:1407-13.
42. Cory S, Adams JM. The Bcl-2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2:647-56.
43. Carlomagno F, Vitagliano D, Guida T, Napolitano M, Vecchio G, Fusco A, et al. The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res 2002;62:1077-82.
44. Strock CL, Park JI, Rosen M, Dionne C, Ruggeri B, Jones-Bolin S, et al. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res 2003;63:5559-63.
45. Hennige AM, Lammers R, Hoppner W, Arlt D, Strack V, Teichmann R, et al. Inhibition of Ret oncogene activity by the protein tyrosine phosphatase SHP1. Endocrinology 2001;142:4441-7.